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Abstract 
In the vasculature, a physiologic production of nitric oxide (NO) is maintained by endothelial nitric oxide syn-
thase (eNOS). Induction of inducible nitric oxide synthase (ÍNOS) under inflammatory conditions (e.g. septic 
shock) resulting 111 high levels of nitric oxide (NO) is believed to be partly responsible for the pathophysiologic 
changes in the vascular system that occur under inflammatory conditions (e.g. septic shock). Both N O S isoforms 
are dependent on the obligatory cofactor tetrahydrobiopterin (BH4). We investigated the selectivity and potency 
of the BH4 analogues 4-amino-BH4 and 5-methyl-BH4 in inhibiting eNOS and iNOS in a murine vascular 
endothelial cell (MVEC) model expressing either eNOS or iNOS under physiologic and inf lammatory conditions, 
respectively. Exogenous BH4 and its precursor sepiapterin both enhanced physiologic eNOS activity in resting 
MVEC, while 4-amino-BH4 slightly inhibited eNOS. 5-methyl-BH4 did not have any effect on eNOS. BH4, sepi -
apterin, and 5-methyi-BH4 had no effect on iNOS in inflammatory activated MVEC. In contrast, 4-amino-BH4 
selectively inhibited iNOS with a potency comparable to the unselective NOS inhibitor Νω-monomethyl-L-argi-
mne (L-NMMA). The present study demonstrates that 4-amino-BH4 selectively and potently inhibits iNOS in 
vascular endothelial cells, while its effect on eNOS is minimal. The selective inhibition of iNOS is a promising 
strategy for the treatment of inflammatory conditions with high output of NO. Further in vivo studies are required 
to determine whether inhibition of N O production by analogues of BH4 offers any advantage compared to inhi-
bition by L-arginine analogues. 
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Recent years clearly established nitric oxide (NO) 
as a key mammalian metabolite for signaling in the 
vascular system in both physiological and pathophysi-
ological states (1). The molecular control of N O syn-
thases (NOS), which catalyze the five electron oxida-
tion of L-arginine in a two-step process yielding L-cit-
rulline and NO, has been elucidated in some detail (2). 
In the physiologic state, vascular endothelial cells con-
stitutively express eNOS protein, and endothelium-
derived N O diffuses into subjacent smooth muscle 
cells to activate soluble guanylate cyclase thereby 
increasing cGMP and resulting in vasorelaxation (3). 
, nitric oxide synthase; pteridine; tetrahydrobiopterin; 
tetrahydrobiopterin 
However, under inflammatory conditions eNOS is 
downregulated whereas activating stimuli induce the 
expression of iNOS m R N A and subsequent "high-out-
put" N O production (4). It is of note that the expression 
of iNOS has been found in murine (5), porcine (6), and 
rat vascular endothelial cells (7, 8), but not in human 
vascular endothelial cells (9, 10). In contrast, vascular 
smooth muscle cells f rom different species, including 
rat and human, express iNOS m R N A and functional 
protein upon stimulation with inf lammatory stimuli 
(11-14). 
Tetrahydrobiopterin (BH4) is essentially required as 
cofactor for all N O S isoforms; for a recent review on 
BH4's functions in the vascular system, see (4). The 
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exact role of BHU in NO catalysis remains intensively 
debated and may include stabilization of the active 
conformation of the enzyme, action as an allosteric 
effector enhancing L-arginine binding, and coupling of 
L-arginine oxidation to NADPH consumption reduc-
ing the ratio of superoxide to NO production, and post-
transcriptional stabilization of NO synthase mRNA. 
Vascular endothelial cells express all enzymes neces-
sary for BH4 generation. They synthesize and secrete 
small amounts of BH4 even in the resting state, and 
inflammatory stimuli increase BH4 synthesis manifold 
in these cells. iNOS in many cell types including vas-
cular smooth muscle cells depends on exogenous BH4 
for full enzymatic activity, rendering NO production 
susceptible to modulation by exogenous BH4 or ana-
logues (4). To date, however, it is not clear whether 
iNOS activity in vascular endothelial cells is also 
prone to modulation by exogenous BHk Given the 
high rate of BH4 synthesis and secretion in these cells, 
we hypothesized that iNOS m vascular endothelial 
cells behaves differently compared to iNOS from other 
cell types devoid of abundant BH4 synthesis. We there-
fore investigated the effects of BH4 and the analogues 
4-amino-BH4 and 5-methyl-BH4 on NO production in 
murine vascular endothelial cells expressing both 
eNOS and iNOS (5). 
Methods 
Chemicals 
5,6,7,8-tetrahydro-L-erythro-biopterin (tetrahydro-
biopterin, BH4), the analogues 4-amino-BH4 and 5-
methyl-BH4, and sepiapterin were purchased from Dr. 
B. Schircks Laboratories (Jona, Switzerland). Murine 
recombinant interferon-y (IFN-γ) was from Peprotech 
Inc. (Rocky Hill, NJ, USA). Lipopolysaçcharide (LPS, 
E. coli 026:B6, Boivin extraction) was from Difco 
(Detroit, MI, USA) and Sigma (St. Louis, MO, USA). 
Ν "-nitro-L-arginine methyl ester (L-NAME) and N° -
monomethyl-L-arginine (L-NMMA) were obtained 
from Sigma. 
Cell cultures 
Murine vascular endothelial cells (MVEC) (15) 
were maintained in a humidified 5% C02/95% air 
atmosphere at 37°C in Iscove's Modified Dulbecco's 
Medium (Cellgro, Mediatech Inc., Ilerndon, VA, 
USA) supplemented with 10% fetal bovine serum 
(heat inactivated, mycoplasma/virus/endotoxin-tested, 
Life Technologies, Rockville, MD, USA), L-glutamine 
(2 mM, Cellgro) and gentamicin (50 μg ml·1, Sigma). 
Cells were seeded in 24-well cluster plates (Corning 
Inc., Corning, NY, USA). Confluent cultures were 
used for experiments. For inflammatory stimulation. 
cells were treated with IFN-γ (100 U ml·1) and LPS 
(10 μg ml1) for 24 or 48 hours as indicated. Cell via-
bility was assessed by trypan blue exclusion and was 
95-98% throughout experiments. 
Determination of NOS isoform mRNA. 
Expression of NOS isoforms was determined by 
reverse-transcriptase PCR using isoform-specific 
primers as described (16). eNOS, 5'TTCACTCTGCC-
CCCAGAGATG3' (sense) and 5'AGAGATCTTCA-
CTGCATTGG3' (antisense), yielding a 611 bp prod-
uct, located at bp 911-1522 of the murine eNOS cDNA 
sequence (17); iNOS, 5ATGGCTTGCCCCTG-
GAAGTTTCT3' (sense) and 5'CCTCTGATGGTGC-
CATCGGGC3' (antisense), yielding a 817 bp product, 
located at bp 192-1009 of the murine iNOS cDNA 
sequence (18). Both iNOS and eNOS were determined 
in the same cDNA preparations. 
Measurement of nitric oxide/nitrite 
NO production was measured as nitrite (NO,-) in 
culture supernatants by the Griess method as described 
(19) with sodium nitrite diluted in complete medium as 
standard. The ratio of nitrite to nitrate was assumed to 
remain constant during all treatment regimens used. 
The detection limit for N0 2 - was 10 pm/well or 
1.0 pmol L 
Statistical analysis 
Results are presented as mean ± SD. One-way 
analysis of variance (ANOVA) for repeated measures 
with Tukey-Kramer Multiple Comparisons Tests were 
performed using InStat version 3.00 (GraphPad, San 
Diego, CA, USA). p<0.05 was considered significant. 
Results 
Effects on eNOS and iNOS mRNA expression and 
NO production during inflammatory stimulation of 
murine vascular endothelial cells (MVEC) 
In accordance with previous findings (5), resting 
MVEC secreted small amounts of NO, detected as 
nitrite in culture supernatants. After 48 hours, 
15.12+4.99 μΜ (range: 8.17 to 29.83 μΜ) nitrite were 
produced by unstimulated MVEC (n=26; data not 
shown). As reported in an earlier study, incubation of 
these cells with IFN-y/LPS resulted in a strong induc-
tion of NO synthesis (5). Accordingly, IFN-γ and LPS-
stimulated MVEC produced 234.01±166.33 μΜ nitrite 
after 48 hours (n=19, data not shown); interexperimen-
tal variations were high, as indicated by the wide range 
from 62.17 to 642.00 μΜ nitrite. As shown in Fig. 1, 
reverse-transcriptase PCR experiments revealed 
expression of eNOS, but not of iNOS mRNA under 
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Figure I. Differential expression of NOS isoforms in 
confluent MVEC. Under resting conditions, only 
endothelial eNOS mRNA was found by RT-PCR 
(upper panel). 24h after stimulation with IFN-γ (100 U 
ml·') and LPS (10 μg ml·1), iNOS mRNA was strongly 
induced, whereas eNOS mRNA disappeared to unde-
tectable levels (lower panel). Therefore, MVEC cells 
switch from eNOS activity under resting to iNOS 
activity under inflammatory condition. Both eNOS 
and iNOS were determined in the same cDNA prepa-
rations. 
resting conditions. In contrast, analysis of mRNA 24h 
after the addition of IFN-γ and LPS showed strong 
expression of iNOS mRNA, whereas eNOS mRNA 
could no longer be detected. These basic experiments 
clearly confirm that unstimulated MVEC switch from 
low output NO production by eNOS to high output NO 
synthesis by iNOS after stimulation with inflammato-
ry stimuli. 
Effects of BH4 and sepiapterin on NO production by 
MVEC 
Fig. 2 shows the effects of increasing concentrations 
of the natural cofactor BH4 and its substituent sepiap-
terin, which is converted intracellularly to BH4 by the 
salvage pathway (4) on NO generation. Both BH4(Fig. 
2A) and sepiapterin (Fig. 2B) slightly enhanced NO 
production by eNOS, e.g. in unstimulated MVEC. Ni-
trite in culture supernatants increased from 14.10+5.33 
in controls to 18.90+7.93 for BH4 at 200 μΜ, n=8, 
p=0.001, and from 13.79+5.12 to 17.42+4.31 for 200 
μΜ sepiapterin, n=4, p<0.0001. In contrast, BH4 and 
sepiapterin failed to influence NO production by iNOS 
in stimulated MVEC (from 190.90+179.83 to 
158.33+208.97 for 200 μΜ BH4, n=4, ρ is not signifi-
cant, and from 220.33±185.46 to 203.721162.61 for 
200 μΜ sepiapterin, n=3, ρ is not significant. 
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Figure 2. Effects of the natural cofactor BH4 and its 
substituent sepiapterin on NO production by MVEC. 
After achievement of confluence, MVEC were incu-
bated without stimulus (open symbols) or treated with 
IFN-γ (100 U ml·') and LPS (10 μg ml·1), and either 
BH4 (A) or sepiapterin (B) was added at the indicated 
concentrations. NO production was measured as nitrite 
in culture supernatants after 48 hours in triplicate wells 
and duplicate measurements. Results are presented as 
% change+SD from corresponding control wells. 
* denotes p<0.01 as compared to corresponding wells 
treated with L-NAME 10 μΜ or 25 μΜ and p<0.05 as 
compared to 50 μΜ. ** p<0.01 compared to corre-
sponding controls. 
Effects of the pteridine analogues 4-amino-BH4 and 
5-methyl-BH4 on NO production by MVEC 
4-amino-BH4 slightly decreased NO production in 
unstimulated MVEC (Fig. 3A), as shown by a decrease 
of nitrite in culture supernatants from 18.42±7.84 in 
control wells to 11.54±4.64 for wells treated with 100 
μΜ 4-amino-BH4 and 12.58±1.11 for wells treated 
with 200 μΜ 4-amino-BH4, n-4, p=0.01. In contrast to 
its slight effect on eNOS, 4-amino-BH4 strongly and 
dose-dependently inhibited iNOS in stimulated MVEC 
(decrease from 167.61+20.04 in controls to 43.56+3.66 
for 200 μΜ 4-ammo-BH4, n=3, pO.OOOl. The other 
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Figure 3. Effects of the pîeridine analogues 4-amino-
BH4 and 5-methyl-BH4 on NO production by MVEC. 
After confluence was achieved, MVEC were incubat-
ed without stimulus (open symbols) or treated with 
IFN-γ (100 U ml"1) and LPS (10 μ δ ml1) and either 4-
amino-BH4 (A) or 5-methyl-BH4 (B) was added as 
indicated. NO production was measured as nitrite in 
culture supernatants after 48 hours in triplicate wells 
and duplicate measurements. Results are presented as 
% change±SD from corresponding control wells. 
* p<0.05 compared to corresponding controls; 
** p<0.01 compared to corresponding controls; 
*** p>0.001 compared to corresponding controls. 
pteridine analogue 5-methyl-BH4 failed to influence 
NO production both in unstimulated as well as in stim-
ulated MVEC (Fig. 3B). In experiments with unstimu-
lated cells, the amount of nitrite in supernatants was 
14.89±3.43 in control wells and 13.39±7.42 in wells 
incubated with 200 μΜ 5-methyl-BH4, n=3, ρ is not 
significant. In stimulated MVEC, supernatant nitrite 
was 267.39±229.91 m controls and 238.00±197.15 at 
200 μΜ 5-methyl-BH4, n=3, ρ is not significant. 
Effects of the L-arginine analogues L-NAME and 
L-NMMA on NO production by MVEC 
Both L-arginine analogues tested, L-NAME and 
L-NMMA, significantly inhibited NO production in 
unstimulated and stimulated MVEC. L-NAME (Fig. 
4A) decreased NO generation by eNOS from 
14.22±4.83 to 8.67±7.04 at a concentration of 200 μΜ 
L-NAME, n=3, p=0.001, and by iNOS from 
344.06±270.57 to 188.50± 176.46 for 200 μΜ 
L-NAME, n=3, p=0.001. L-NMMA (Fig. 4B) inhibit-
ed NO production by eNOS, as shown by a decrease of 
nitrite in culture supernatants from 16.04+2.87 to 
10.33±4.53 for 200 μΜ L-NMMA, n=4, p=0.01, and it 
decreased NO generation by iNOS from 228.17±95.56 
to 71.17±18.77 for 200 μΜ L-NMMA, n=3, p-0.0005. 
Discussion 
This study shows that highly upregulated NO pro-
duction in MVEC is regulated on the NOS isoform 
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Figure 4. Effects of the L-arginine analogues L-
NAME and L-NMMA on NO production by MVEC. 
Confluent MVEC were incubated without stimulus 
(open symbols) or treated with IFN-γ (100 U ml1) and 
LPS (10 μg ml1), and increasing concentrations of 
either L-NAME (A) or L-NMMA (B) were as indicat-
ed. NO production was measured as nitrite in culture 
supernatants after 48 hours in triplicate wells and 
duplicate measurements. Results are presented as % 
change±SD from corresponding control wells. 
* p<0.05 compared to corresponding controls; 
** p<0.01 compared to corresponding controls; 
*** p<0.001 compared to corresponding controls. 
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gene transcription level, confirming the "switch 
model" of NOS isoforms under inflammatory condi-
tions. Using this unique cellular model, we demon-
strate the selective inhibition of iNOS by 4-amino-
BH4, and an independence of vascular endothelial 
iNOS from exogenous BH4 for full enzymatic activity. 
The data outlined herein unequivocally show that 
basal NO production of MVEC can solely be attributed 
to eNOS activity. However, upon stimulation with 
proinflammatory molecules, iNOS expression is 
induced while eNOS is downregulated. The reduction 
of eNOS mRNA and protein levels following activa-
tion by cytokines or endotoxin has also been demon-
strated in cultured human and bovine endothelial cells, 
and this effect could at least partially be attributed to 
enhanced degradation rates of eNOS transcripts (5, 9, 
20-23). Therefore, MVEC switch their active NOS iso-
form in dependence of the presence of inflammatory 
signals, i.e. from low-output NO production by eNOS 
under physiological (non-inflammatory) conditions to 
high-output NO generation by iNOS under inflamma-
tory situations, referred to as "switch model" previous-
ly (4). Although eNOS mRNA is downregulated to 
undetectable levels within several hours after inflam-
matory stimulation, preexisting eNOS protein may 
continue to contribute to the total production of NO 
during the first days under inflammatory conditions 
(5); however, this seems to be negligible in view of the 
large amounts of NO generated simultaneously by 
iNOS. 
Resting vascular endothelial cells constitutively 
synthesize small amounts of BH4. Although the rate of 
enzyme activity and resulting BH4 synthesis may 
depend on experimental conditions and probably also 
on the type of endothelial cell assessed, this basic char-
acteristic has been found both in freshly isolated cells 
as well as in cells after prolonged culturing (4). In 
addition, our findings that sepiapterin slightly 
increased (and additional BH4 tended to increase) the 
amount of NO production of vascular endothelial 
eNOS are in line with observations made by others and 
underline the regulatory capacity of the pteridine 
cofactor for endothelial NO production under non-
inflammatory conditions. However, in vivo data sug-
gest that under physiologic conditions levels endoge-
nous BH4 are nearly saturating and barely a limiting 
factor for optimal or near optimal endothelial eNOS 
activity, and only very high concentrations of BH4 
resulted in endothelium-dependent vasorelaxation in 
animal and human studies (24, 25). 
It is generally believed that iNOS activity largely 
depends on exogenous BH4, i.e. that endogenous BH4 
biosynthesis does not suffice to support iNOS for full 
enzymatic activity. Although BH4 biosynthesis is 
induced by inflammatory stimuli in cultured cells, 
intrinsic BH4 availability has nevertheless been 
demonstrated to be a limiting factor for iNOS activity 
in many cell types including macrophages, mesangial 
cells, vascular smooth muscle, and fibroblasts, render-
ing NO production susceptible to modulation of intra-
cellular BH4 levels by inhibition of BH4 biosynthesis 
or exogenous BH4 addition (4). However, the present 
study shows strikingly different characteristics for vas-
cular endothelial cells. The vascular endothelium pro-
duces and secrets abundant amounts of BH4 upon 
inflammatory stimulation, as shown for cells of murine 
(26) and human (27) origin. The increase in de novo 
BHi biosynthesis occurs early after inflammatory 
stimulation and may even lead to transiently increased 
NO production by eNOS despite the concomitant 
decrease of total eNOS protein. In view of this high 
level BHa biosynthesis in endothelial cells under 
inflammatory conditions, it is not surprising that 
endogenous BH4 levels are saturating to fully serve 
endothelial iNOS protein. Moreover, since most of the 
newly synthesized BH4 is secreted, probably even vec-
torially into the basal direction (4), endothelial BH4 
may serve underlying smooth muscle cells with addi-
tional cofactor needed for full iNOS activity, thereby 
accounting for an inflammatory endothelium-derived 
relaxing factor. On the other hand, BH4 is a potent 
antioxidative and reactive oxygen scavenging agent, 
preventing peroxynitrite formation when present in 
saturating amounts (28). The high amount of BHi pro-
duced by endothelial cells in inflammation or sepsis 
could therefore be beneficial. Thus, an inhibition of 
iNOS and not of BH4 synthesis seems desirable. 
The 4-amino analogue of BH4 binds with high affin-
ity and the same potency to both recombinant eNOS 
and iNOS and strongly interferes with stimulation of 
the enzymes by exogenous BH4, although 4-amino-
BH4 shares the same allosteric effects, namely stabi-
lization of the active dimers and low-to-high spin tran-
sition of the heme, as the natural cofactor (29, 30). In 
contrast to these findings obtained with purified pro-
teins, 4-amino-BH4 was much less effective in inhibit-
ing NO formation in cultured porcine endothelial cells 
(expressing eNOS) compared to cultured murine 
fibroblasts or human adenocarcinoma cells (expressing 
iNOS) (29). Despite the fact that the effect of 4-amino-
BH4 critically depended on intracellular BH4 levels, 
the selectivity towards inhibition of iNOS could not 
simply be explained by different intracellular BH4 lev-
els, and therefore, it was suggested that the high-affin-
ity binding of the inhibitor during protein expression 
may be responsible for the difference, since the 
turnover of iNOS protein is much more rapid than that 
of eNOS (half-life approximately 3 hours vs. 20 hours) 
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(29). Likewise, 4-amino- BH4 was shown to be fairly 
selective in inhibiting iNOS in an in vivo vessel strip 
model of endotoxemia; in this study, the pteridine 
antagonist had to be added shortly after the artery 
strips were treated with inflammatory stimuli (31), 
again suggesting that the apparent selectivity of 4-
amino- BH4 may be related to high-affinity binding of 
the inhibitor during protein expression. 
The present data are in full agreement with those 
obtained by (29) and (31) and show that a preferential 
inhibition of the iNOS protein by 4-amino-BH4 can 
also be demonstrated in cells expressing both NOS iso-
forms, thereby excluding the possibility of cell type 
differences as an explanation for the observed effect. 
Nevertheless, different situations will be encountered 
in vivo in the human vasculature, where endothelial 
BH4 might compete with exogenous 4-amino-BH4 for 
binding on the pteridine-sites of smooth muscle cell 
iNOS, and in vivo experiments will ultimately be 
required to determine whether 4-amino-BH4 displays a 
real" selectivity for iNOS thereby offering an inter-
esting therapeutic tool for the treatment of NO over-
production by iNOS under inflammatory conditions in 
humans. 
The 5-methyl-analogue of BHU has previously been 
shown to substitute BH4 as a cofactor (32); however, at 
high concentrations of purified NOS, the autoxidation 
resistant 5-methyl-BH4 may result in fully coupled NO 
generation and, subsequently, NO-induced autoinhibi-
Π011 of NOS (33). Therefore, the effect of 5-methyl-
BH4 on net amounts of NO may be critically depend-
ent on the experimental conditions. In the present 
study we did not find any significant effect of 5-
methyl-BIl4 neither on eNOS nor 011 iNOS activity, 
rather excluding the use of this analogue to pharmaco-
logically modulate NO production in the vasculature. 
In summary, vascular endothelial cells switch from 
eNOS under resting to iNOS under inflammatory con-
ditions; the concomitant increase in endogenous BH4 
biosynthesis make these cells independent from exoge-
nous sources for the pteridine cofactor for full enzy-
matic activity. 4-amino BH4 was revealed as a prefer-
ential inhibitor for iNOS in vascular endothelial cells, 
whereas 5-methyl-BH4 was largely ineffective. Further 
in vivo experiments are required to confirm these 
observations and to determine whether inhibition of 
NO production by analogues of BH4 offers any advan-
tage over inhibition by L-arginine-analogues in the 
treatment of human inflammatory diseases. 
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